Javascript must be enabled to continue!
Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies
View through CrossRef
Cisplatin is a highly effective chemotherapeutic agent that is widely used to treat solid organ malignancies. However, serious side effects have been associated with its use, such as bilateral, progressive, irreversible, dose-dependent neurosensory hearing loss. Current evidence indicates that cisplatin triggers the production of reactive oxygen species in target tissues in the inner ear. A variety of agents that protect against cisplatin-induced ototoxicity have been successfully tested in cell culture and animal models. However, many of them interfere with the therapeutic effect of cisplatin, and therefore are not suitable for systemic administration in clinical practice. Consequently, local administration strategies, namely intratympanic administration, have been developed to achieve otoprotection, without reducing the antitumoral effect of cisplatin. While a considerable amount of pre-clinical information is available, clinical data on treatments to prevent cisplatin ototoxicity are only just beginning to appear. This review summarizes clinical and experimental studies of cisplatin ototoxicity, and focuses on understanding its toxicity mechanisms, clinical repercussions and prevention strategies.
Title: Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies
Description:
Cisplatin is a highly effective chemotherapeutic agent that is widely used to treat solid organ malignancies.
However, serious side effects have been associated with its use, such as bilateral, progressive, irreversible, dose-dependent neurosensory hearing loss.
Current evidence indicates that cisplatin triggers the production of reactive oxygen species in target tissues in the inner ear.
A variety of agents that protect against cisplatin-induced ototoxicity have been successfully tested in cell culture and animal models.
However, many of them interfere with the therapeutic effect of cisplatin, and therefore are not suitable for systemic administration in clinical practice.
Consequently, local administration strategies, namely intratympanic administration, have been developed to achieve otoprotection, without reducing the antitumoral effect of cisplatin.
While a considerable amount of pre-clinical information is available, clinical data on treatments to prevent cisplatin ototoxicity are only just beginning to appear.
This review summarizes clinical and experimental studies of cisplatin ototoxicity, and focuses on understanding its toxicity mechanisms, clinical repercussions and prevention strategies.
Related Results
Abstract 1490: RAD51C-deficient cancer cells require DNA polymerase zeta to bypass cisplatin-induced lesion
Abstract 1490: RAD51C-deficient cancer cells require DNA polymerase zeta to bypass cisplatin-induced lesion
RAD51C is a RAD51 paralog protein that mediates RAD51 filament formation on single-stranded DNA (ssDNA) in a canonical homologous recombination (HR) pathway. This step is vital for...
Predictive model for aminoglycoside induced ototoxicity
Predictive model for aminoglycoside induced ototoxicity
BackgroundIrreversible hearing loss is a well-known adverse effect of aminoglycosides, however, inability to accurately predict ototoxicity is a major limitation in clinical care. ...
Possible ameliorative effects of pentoxifylline on cisplatin-induced ototoxicity in rats: a study with hearing test, light, and scanning electron microscopy
Possible ameliorative effects of pentoxifylline on cisplatin-induced ototoxicity in rats: a study with hearing test, light, and scanning electron microscopy
Cisplatin is an antineoplastic drug widely used to treat various types of cancer. Ototoxicity is still cisplatin’s most critical side-effect. Some patients may experience dose limi...
The effects of recombinant klotho in cisplatin‐induced ovarian failure in mice
The effects of recombinant klotho in cisplatin‐induced ovarian failure in mice
AbstractAimTo investigate whether recombinant klotho given concomitantly with cisplatin is effective in preventing cisplatin‐induced ovarian damage.MethodsThirty‐two adult female m...
Intratympanic Dexamethasone to Prevent Cisplatin Ototoxicity
Intratympanic Dexamethasone to Prevent Cisplatin Ototoxicity
ObjectiveTo determine whether intratympanic administration of dexamethasone reduces ototoxicity from systemic cisplatin.Study DesignProspective animal study.SettingCisplatin chemot...
Extended-Interval Aminoglycoside Administration for Children: A Meta-analysis
Extended-Interval Aminoglycoside Administration for Children: A Meta-analysis
Background. There has been a long-standing debate regarding whether aminoglycosides should be administered on a multiple daily dosing (MDD) or once-daily dosing (ODD) schedule. Sev...
Abstract 1598: Epigenetic priming using azacitidine improves cisplatin response in diffuse large B-cell lymphoma cell lines via endogenous retroviruses induced viral mimicry
Abstract 1598: Epigenetic priming using azacitidine improves cisplatin response in diffuse large B-cell lymphoma cell lines via endogenous retroviruses induced viral mimicry
Abstract
Background and purpose Although majority of patients with diffuse large B-cell lymphoma (DLBCL) achieve and complete remission after first-line rituximab-CH...
Possible Protective Effect of Sertraline against Cisplatin‐Induced Ototoxicity: An Experimental Study
Possible Protective Effect of Sertraline against Cisplatin‐Induced Ototoxicity: An Experimental Study
Background/Objective. Cisplatin is a widely used chemotherapeutic agent, but its ototoxicity side effect can occur in the majority of patients. Lots of agents were tried to prevent...

